Sign In
Buy CSU
$33.30
+0 (+0%)
At Close: Jul 20, 2022
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce
Constellation Software Inc. (TSE:CSU) Given Average Rating of “Moderate Buy” by Analysts
05:08am, Wednesday, 08'th Apr 2026
Shares of Constellation Software Inc. (TSE: CSU - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the company, Marketbeat
Constellation Software Inc. Announces Mark Leonard's Decision to not Stand for Re-Election to Board of Directors
07:31pm, Friday, 27'th Mar 2026
TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) (“Constellation”) announced today that Mark Leonard, the founder and former President of Constellation, will not s
Constellation Software Inc. (CSU:CA) Q4 2025 Earnings Call Transcript
12:47pm, Monday, 09'th Mar 2026
Constellation Software Inc. (CSU:CA) Q4 2025 Earnings Call Transcript
- Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks - - Greatly improved qu
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
06:29am, Friday, 27'th Feb 2026
Basel, February 27, 2026 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
01:15am, Monday, 23'rd Feb 2026
Basel, February 23, 2026 – Novartis will present data from five key abstracts evaluating the highly selective oral Bruton's tyrosine kinase inhibitor (BTKi) Rhapsido® (remibrutinib) in chronic spon
Constellation Software Inc. Announces Conference Call to Discuss Fourth Quarter Results
05:51pm, Tuesday, 17'th Feb 2026
TORONTO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced today it will host a fourth quarter conference call and live audio webcast on March 10, 2026 at 8:00 a.m. ET
Constellation Software (TSE:CSU) Reaches New 52-Week Low – Time to Sell?
04:22am, Tuesday, 20'th Jan 2026
Constellation Software Inc. (TSE: CSU - Get Free Report)'s share price reached a new 52-week low during trading on Tuesday. The company traded as low as C$2,791.01 and last traded at C$2,791.01, with
Constellation Software Inc. Announces Annual Interest Rate for Series 1 Debentures
05:07pm, Monday, 19'th Jan 2026
TORONTO, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX: CSU, TSX: CSU.DB) (the “Company”) announced today that the interest rate applicable to the unsecured subordinated float
Barry Alan Symons Sells 2,500 Shares of Constellation Software (TSE:CSU) Stock
04:06am, Monday, 15'th Dec 2025
Constellation Software Inc. (TSE: CSU - Get Free Report) insider Barry Alan Symons sold 2,500 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of
InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)
07:30am, Monday, 10'th Nov 2025
Phase 2a data support oral C5aR inhibitor INF904 as a potentially transformational and best-in-class immunomodulatory agent, indicating strong potential for efficacy and no safety signals of concern I
Steady Hands In Shifting Skies: Why CSU Remains A Long-Term Star
10:27am, Friday, 24'th Oct 2025
Constellation Software presents a compelling long-term investment opportunity after a 25% stock price decline driven by AI concerns and leadership transition. CSU's decentralized structure, focus on m
Constellation Software Inc. Announces Release Date for Third Quarter Results
05:12pm, Monday, 20'th Oct 2025
TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced today it intends to release its third quarter results on November 7, 2025.
